FTSE 100 today: U.K. inflation rises above expected, index falls; GBP climbs
CRISPR Therapeutics AG (NASDAQ:CRSP), a leader in gene-editing therapies, announced the results of its 2025 Annual General Meeting held on June 5, 2025, where shareholders voted on several key proposals. The meeting saw the approval of amendments to the company’s Articles of Association, the election of board members, and the ratification of financial statements, among other items.
Shareholders approved the Swiss management report, consolidated financial statements, and the statutory financial statements for the year ended December 31, 2024. They also endorsed the appropriation of financial results, discharged the Board of Directors and Executive Committee members from personal liability, and elected or re-elected eleven board members, including the chairman. Additionally, the Compensation Committee members were elected or re-elected, and the compensation for the Board of Directors and Executive Committee was approved.
The company’s independent voting rights representative and auditors were re-elected, with Ernst & Young AG set to serve as the statutory auditor and Ernst & Young LLP as the independent registered public accounting firm for the year ending December 31, 2025.
The meeting also saw the approval of increasing the maximum size of the Board of Directors and the transaction of any other business that may properly come before the Annual Meeting.
The voting results are final, and the amended and restated Articles of Association will become effective upon registration in the Commercial Register in the canton of Zug, Switzerland, subject to the Swiss Federal Commercial Authority’s approval.
This information is based on a press release statement.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.